Small molecule · developed by Passage Bio
PBFT02 is a drug studied in frontotemporal dementia, including forms linked to GRN and C9orf72 gene variants.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04747431 | Phase 1/2 | Frontotemporal Dementia | Terminated | PASG |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
C9orf72Dementia FrontotemporalFrontotemporal DementiaFTDFTD-GRN
See PASG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PASG catalysts and pipeline →